14th Jul 2015 09:07
LONDON (Alliance News) - Ergomed PLC said Tuesday morning that the first patient has been recruited unto a Phase IIa study of Lorediplon in adults with an insomnia disorder, which it is undertaking with co-development partner Ferrer Internacional SA.
The study is scheduled to be completed by the fourth quarter of 2016.
"Lorediplon has previously demonstrated promising results in preclinical and clinical studies, and we believe it has the potential to treat patients within insomnia and related sleep disorders which remains an underserved market where new treatments are needed," said Chief Executive Officer of Ergomed Miroslav Reljanovic in a statement.
Shares in Ergomed are untraded Tuesday. It last closed at 181.10 pence.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
ERGO.L